Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Comparative immunogenicity under held conditions of two recombinant hepatitis B vaccines in 8-10-year-old children
Autore:
Duval, B; Boulianne, N; De Serres, G; Laflamme, N; De Wals, P; Masse, R; Trudeau, G; Delage, G; Desjardins, L;
Indirizzi:
CHUQ, Unite Rech Sante Publ, Ctr Rech, Beauport, PQ G1E 7G9, Canada CHUQ Beauport PQ Canada G1E 7G9 l, Ctr Rech, Beauport, PQ G1E 7G9, Canada Univ Sherbrooke, Fac Med, Sherbrooke, PQ, Canada Univ Sherbrooke Sherbrooke PQ Canada ke, Fac Med, Sherbrooke, PQ, Canada Minist Sante & Serv Sociaux, Quebec City, PQ, Canada Minist Sante & Serv Sociaux Quebec City PQ Canada uebec City, PQ, Canada Direct Sante Publ Saguenay Lac St Jean, Chicoutimi, PQ, Canada Direct Sante Publ Saguenay Lac St Jean Chicoutimi PQ Canada , PQ, Canada Lab Sante Publ Quebec, St Anne De Bellevue, PQ, Canada Lab Sante Publ Quebec St Anne De Bellevue PQ Canada Bellevue, PQ, Canada Ctr Hosp Univ Quebec, Quebec City, PQ, Canada Ctr Hosp Univ Quebec QuebecCity PQ Canada ebec, Quebec City, PQ, Canada
Titolo Testata:
VACCINE
fascicolo: 15, volume: 18, anno: 2000,
pagine: 1467 - 1472
SICI:
0264-410X(20000214)18:15<1467:CIUHCO>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
VACCINATION; ADULTS; SAFETY; INFANTS; MEMORY; VIRUS; RISK; DNA;
Keywords:
hepatitis B, vaccination; immunigenicity;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Agriculture,Biology & Environmental Sciences
Life Sciences
Citazioni:
35
Recensione:
Indirizzi per estratti:
Indirizzo: Duval, B CHUQ, Unite Rech Sante Publ, Ctr Rech, Pavillon CHUL,2400 Estimauville, Beauport, PQ G1E 7G9, Canada CHUQ Pavillon CHUL,2400 Estimauville Beauport PQ Canada G1E 7G9 a
Citazione:
B. Duval et al., "Comparative immunogenicity under held conditions of two recombinant hepatitis B vaccines in 8-10-year-old children", VACCINE, 18(15), 2000, pp. 1467-1472

Abstract

The immunogenicity of two hepatitis B vaccines was compared in 8-10-year-old children immunized in a school program. One year apart, 1129 children received Engerix-B 10 mu g vaccine (EB), and 1126 received Recombivax-HB 2.5 mu g (RB), following the 0, 1, 6 schedule. Blood samples were collected onemonth after the third dose. Anti-Hbs were measured by commercial radioimmunoassay, In the EB group, 99.1% of the children seroconverted (greater thanor equal to 2 IU/l) compared to 99.7% in the RHB group (p = 0.09). The seroprotection rate (greater than or equal to 10 IU/l) was similar for both groups: 98.9% in the EB group and 99.2% in the RE group (p = 0.66). However, GMCs of anti-HBs were higher in children given EB compared to those given RE (7307 vs. 3800 mIU/ml, p < 0.0001). This study showed that both vaccines were highly immunogenic, in the course of a regular field immunization program. However, the difference observed in the antibody levels attained according to the vaccine may play a role in the longterm protection of these children. (C) 2000 Elsevier Science Ltd, All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/12/20 alle ore 14:48:13